Articles on antipsychotics from NPS RADARArticles on antipsychotics from NPS RADAR

Title Content Type Date Description
Long-acting intramuscular injectable form of paliperidone (Invega Sustenna) for schizophrenia Professional publication - NPS RADAR - Brief item 2011-12-01 00:00:00 The long-acting intramuscular injectable form of paliperidone (Invega Sustenna) for schizophrenia was listed on the Pharmaceutical Benefits Scheme on 1 December 2011*
Asenapine (Saphris) for schizophrenia or bipolar I disorder (acute mania or maintenance) Professional publication - NPS RADAR - Review 2011-12-01 00:00:00 Asenapine has a similar spectrum of benefits and harms to that of other antipsychotics. Asenapine wafers must be taken sublingually twice daily, with no food or drink for 10 minutes afterwards, and are ineffective if swallowed.
Quetiapine (Seroquel and Seroquel XR) bipolar disorder listings expanded Professional publication - NPS RADAR - Brief item 2010-12-01 00:00:00 From 1 December 2010, the streamlined authority listings of quetiapine (Seroquel) and quetiapine extended-release tablets (Seroquel XR) will include monotherapy for maintenance treatment of bipolar I disorder.
Olanzapine depot injection (Zyprexa Relprevv) for schizophrenia Professional publication - NPS RADAR - Review 2009-12-01 00:00:00 Olanzapine pamoate is a long-acting injectable form of olanzapine. Post-injection syndrome can occur: monitor for signs and symptoms for at least 3 hours after administration.
Ziprasidone (Zeldox): another atypical antipsychotic listed for acute mania in bipolar disorder Professional publication - NPS RADAR - Brief item 2009-04-01 00:00:00 Ziprasidone’s efficacy in acute mania comes from 2 short trials. Be aware of dosing, which is twice daily with food. Although weight gain is less likely than with other atypical antipsychotics, there are few data about long-term risks, including diabetes.
Quetiapine extended-release tablets (Seroquel XR) PBS listed for schizophrenia Professional publication - NPS RADAR - Brief item 2008-12-01 00:00:00 Quetiapine extended-release tablets (Seroquel XR) were added to the Schedule of Pharmaceutical Benefits on 1 November 2008 as a streamlined authority-required listing for schizophrenia. The extended-release tablets come in different strengths to the existing immediate-release tablets, and dosing and administration has changed slightly. Prescribers will need to instruct patients carefully to prevent confusion between the two formulations.
Paliperidone (Invega) for schizophrenia Professional publication - NPS RADAR - Review 2008-04-01 00:00:00 Information on use of paliperidone (Invega) for schizophrenia, including safety and dosing issues.
Quetiapine (Seroquel) PBS listed for acute mania Professional publication - NPS RADAR - Brief item 2007-12-01 00:00:00 PBS listing of quetiapine (Seroquel) was extended to include acute mania associated with bipolar disorder, with streamlined authority allowing an episode of acute mania to be treated for up to 6 months.
Aripiprazole (Abilify) for schizophrenia Professional publication - NPS RADAR - Review 2004-05-01 00:00:00 Reviews use of aripiprazole for schizophrenia, including efficacy studies and PBS listing on cost-minimisation basis against olanzapine.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

RSS FeedRSS feed

Date published: 2009-10-28 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.